[ad_1]
Researchers at the Institute of Cancer Research in the United Kingdom have responded to the new treatment in more than 25% of patients with advanced drug-resistant cancers, more than a quarter of cervical and bladder tumors and nearly 15% of tumors ovary and lung.
The new and innovative drug, tisotumab vedotin (TV), releases a toxic substance that kills cancer cells from the inside.
The results, published in The Lancet Oncology, are so positive that the drug has now moved to phase II cervical cancer trials and will be tested in a range of additional solid tumor cancers.
The researchers conducted a global clinical trial of nearly 150 patients with different types of cancer who stopped responding to standard treatments.
They discovered that a significant minority of cancer patients had responded to the drug, their tumors contracting or stopping to develop.
The researchers observed responses in 27% of patients with bladder cancer, 26.5% of cervical cancer, 14% of ovarian cancer , 13% of a esophagus, 13% of a non-small cell lung and 7% of endometrial cancer.
Responses lasted on average 5.7 months, and up to 9.5 months in some patients, the researchers said.
Metastatic cancer: myths versus facts
Verification of the facts
July 9, 2018
Metastatic cancer, also called advanced cancer, starts in one organ and then spreads to other organs in the body. Dr. Rucha Kaushik, consultant, bad cancer specialist surgeon, hospital and Hinduja Hospital PD, is destroying some myths badociated with high grade cancer. Read also: Metastatic cancer – all you need to know about the disease that Sonali Bendre fights
Television is made of a toxic drug attached to the tail of an antibody. It is designed to look for a receptor called "tissue factor" – present at high levels on the surface of many cancer cells and badociated with poorer survival.
Tissue factor binding attracts the drug to cancer cells, where it can kill them from within.
The trial initially recruited 27 patients to badess the safety and establish the correct dose, before moving on to another 120 patients, mainly to determine if the drug was reaching the right target, but also to determine its effect on patients. you die.
The majority of patients at the beginning of the trial had advanced cancer (spread locally or around the body) that had already been treated with resistance to three different types of treatment and had become resistant to it.
Television is now being tested in other types of cancer, including cancers of the gut, pancreas, squamous cell lung, as well as in a phase II trial as a treatment second-line cancer of the cervix.
"What's so exciting about this treatment, is that its mechanism of action is completely new.It acts as a Trojan horse to infiltrate into cancer cells and kill them." inside, "said Professor Johann de Bono, a professor at the Institute for Research Against Cancer.
"Our first study showed that it could potentially treat a large number of cancer types, especially those with very low survival rates," de Bono said.
"The television has manageable side effects, and we found good responses in patients of our trial, all with advanced-stage cancer, who had been heavily pre-treated with other drugs and who did not Had more choice, "he said. .
Researchers have already initiated further trials of this drug in different types of tumors and as a second-line treatment for cervical cancer, where response rates were particularly high.
They are also developing a test to select the patients most likely to respond.
if(geolocation && geolocation != 5) { !function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '338698809636220'); fbq('track', 'PageView'); }
[ad_2]
Source link